BioRestorative TherapiesFRA:9OF +4.97%51 PS Ratio is 9.94 as of Jul. 03, 2026, which is 85% below its 10-year median of 64.88. GuruFocus rates FRA:9OF with a GF Score™ of 51/100 and a GF Value™ of €1.28 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 933 Biotechnology companies, BioRestorative Therapies ranks worse than 51.34% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioRestorative Therapies's share price is €0.338.
BioRestorative Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03. Hence, BioRestorative Therapies's PS Ratio for today is 9.94.
The historical rank and industry rank for BioRestorative Therapies's PS Ratio or its related term are showing as below:
FRA:9OF'
s PS Ratio Range Over the Past 10 Years
Min: 0.03 Med: 64.88 Max: 529.41
Current: 10.25
During the past 13 years, BioRestorative Therapies's highest PS Ratio was 529.41. The lowest was 0.03. And the median was 64.88.
FRA:9OF's PS Ratio is ranked worse than 51.34% of 933
companies
in the Biotechnology industry
Industry Median: 9.64
vs FRA:9OF: 10.25
BioRestorative Therapies Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of BioRestorative Therapies was -18.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 6.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -10.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -64.80% per year.
During the past 13 years, BioRestorative Therapies's highest 3-Year average Revenue per Share Growth Rate was 10.10% per year. The lowest was -89.80% per year. And the median was -51.80% per year.
Back to Basics: PS Ratio
BioRestorative Therapies (FRA:9OF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioRestorative Therapies's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioRestorative Therapies PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's PS Ratio distribution charts can be found below:
* The bar in red indicates where BioRestorative Therapies's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BioRestorative Therapies's Share Price of today is €0.338. BioRestorative Therapies's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BioRestorative Therapies (FRA:9OF) has a PS Ratio of 9.94 as of Jul. 03, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioRestorative Therapies and its competitors. This is 85% below median its historical median of 64.88. Over the past decade, BioRestorative Therapies' PS Ratio has ranged from 0.03 to 529.41. According to the industry distribution chart, BioRestorative Therapies ranks #479 out of 933 companies in the Biotechnology industry, placing it in the top 51.3%.
Is BioRestorative Therapies' PS Ratio too high?
BioRestorative Therapies' current PS Ratio of 9.94 is 85% below median its 10-year median of 64.88. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 529.41. The Biotechnology industry median PS Ratio is 9.64. BioRestorative Therapies' value of 9.94 is 3.1% above this industry median. Based on the distribution chart, BioRestorative Therapies ranks #479 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' PS Ratio compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #479 out of 933 companies for PS Ratio. This places BioRestorative Therapies in the lower half of its industry. The industry median PS Ratio is 9.64. BioRestorative Therapies' value of 9.94 is 3.1% above this benchmark. Historically, BioRestorative Therapies' own PS Ratio has ranged from 0.03 to 529.41 over the past decade. While the company's 10-year median is 64.88 vs. the industry median of 9.64, BioRestorative Therapies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.64, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioRestorative Therapies's current PS Ratio of 9.94 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median PS Ratio is 9.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current PS Ratio is 9.94, which is 85% below median its own 10-year median of 64.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.28, compared to a current price of €0.34 — trading 73.6% below its estimated fair value. The current PS Ratio is 9.94, which is 85% below median its 10-year median of 64.88 and 3.1% above the Biotechnology industry median of 9.64. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current PS Ratio is 9.94 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?
Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued.
The current stock price of €0.34 is trading 73.6% below its estimated GF Value™ of €1.28.
GuruFocus considers BioRestorative Therapies to be Possible Value Trap.
Key valuation signals for FRA:9OF:
PS Ratio: 9.94 (85% below median its 10-year median of 64.88)
GF Value™: €1.28 vs. price of €0.34 (73.6% below fair value)
Industry Position: 3.1% above the Biotechnology median (#479 of 933)
No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score
Get the complete analysis for FRA:9OF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9OF has been successfully added to your 
